

Docket No.: 22116-00005-US3

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Christine L. O'Day et al.

Application No.: 09/396,523

Filed: September 15, 1999

Art Unit: 1621

For: NOVEL POLYAMINE ANALOGUES AS

THERAPEUTIC AND DIAGNOSTIC

AGENTS

Examiner: P. G. O'Sullivan

Confirmation No.: 7553

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement, pursuant to 37 CFR 1.114(c), accompanies the Request for Continued Examination (37 CFR 1.114) submitted herewith.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Application No.: 09/396,523 Docket No.: 22116-00005-US3

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0185, under Order No. 22116-00005-US5.

Dated: February 28, 2006

Respectfully submitted,

Burton A. Amernick

Registration No.: 24,852

CONNOLLY BOVE LODGE & HUTZ LLP Correspondence Customer Number: 30678

Attorney for Applicant

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many she ets as necessary)

1036 83	many	3116 613	us nece	33 41 97

Complete if Known					
Application Number 09/396,523 Conf.# 7553					
Filing Date September 15, 1999					
First Named Inventor	Christine L. O'Day				
Art Unit	1621				
Examiner Name	P. G. O'Sullivan				
Attorney Docket Number	22116-00005-US3				

	U.S. PATENT DOCUMENTS				
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear

3

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
IIII III III	140.	Country Code - Number - And Code (II Known)	MM-DD-TTTT		or Relevant Pigures Appear	_

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA**	Gallop, M.A., et al., "Applications of Combinatorial Technologies to Drug Discovery. Background and Peptide Combinatorial Libraries.," J. MED. CHEM., (1994) 37(9): 1233-51.	
	CB**	Ganem, B., "New Chemistry of Naturally Occuring Polyamines," ACC. CHEM. RES., (1982) 15:290-8.	
	CC**	Ganem, B., et al., "Chemistry of Naturally Occurring Polyamines. II. Unsaturated Spermidine and Spermine Derivatives," J. ORG. CHEM., (1987) 52:5044-6.	
	CD**	Ganem, B., et al., "Chemistry of Naturally Occuring Polyamines. 10. Nonmetabolizable Derivatives of Spermine and Spermidine," J. ORG. CHEM., (1986) 51:4856-61.	
	CE**	Goodnow, Jr. R.A., et al., "Oligomer Synthesis and DNA/RNA Recognition Properties of a Novel Oligonucleotide Backbone Analog: Glucopyranosyl Nuclei Amide (GNA), "TETRAHEDRON LETT., (1997) 38(18):3199-3202.	
	CF**	Goodnow, Jr., R.A., et al., "Synthesis of Thymine, Cytosine, Adenine, and Guanine Containing N-Fmoc Protected Amino Acids: Building Blocks for Construction of Novel Oligonucleotide Backbone Analogs," TETRAHEDRON LETT., (1997) 38(18):3195-8.	
	CG**	Gordon, E.M., et al., "Applications of Combinatorial Technologies to Drug Discovery Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions," J. MED. CHEM., (1994) 37(10): 1385-1401.	
	CH**	Gorus, F., et al., "Applications of Bio- and Chemiluminescence in the Clinical Laboratory," CLIN. CHEM., (1979) 25(4): 512-9.	
	CI**	Han, H. et al., "Liquid-Phase Combinatorial Synthesis," PROC. NATL. ACAD. SCI. USA, (1995) 92:6419-23.	
	CJ**	Hernandez, A.S. et al., "Solid-Supported tert-Alkoxycarbonylation Reagents for Anchoring of Amines During Solid Phase Organic Synthesis," J. ORG. CHEM., (1997) 62:3153-7.	
	CK**	Huber, M. et al., "2,2'-Dithiobis (N-ethyl-spermine-5-carboxamide) Is a High Affinity, Membrane-Impermeant Antagonist of the Mammalian Polyamine Transport System," J. BIOL. CHEM., (1996) 271(44):27556-63.	
	CL**	Laguzza, B.C., et al., "A New Protecting Group For Amines. Synthesis of Anticapsin from L-Tyrosine," TETRAHED. LETT., (1981) 22(16):1483-6.	

Examiner	Date	
Signature	Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ubstitute for form 1449A/B/PTO

2

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many she ets as necessary)

of

3

Complete if Known					
Application Number 09/396,523 Conf.# 7553					
Filing Date	September 15, 1999				
First Named Inventor	Christine L. O'Day				
Art Unit	1621				
Examiner Name	P. G. O'Sullivan				
Attomey Docket Number	22116-00005-US3				

CM**	Lakanen, J.R., et al., "α-Methyl Polyamines: Metabolically Stable Spermidine and Spermine Mimics Capable of Supporting Growth in Cells Depleted of Polyamines," J. MED. CHEM., (1992) 35:724-34.	
CN**	Lee, J., "Facile Preparation of Cyclopropylamines from Carboxamides," J. ORG. CHEM., (1997) 62:1584-5.	
CO***	Li, Y. et al, "Synthesis and Antitumor Evaluation of a Highly Potent Cytotoxic DNA Cross- Linking Polyamine Analogue, 1, 12-Diaziridinyl-4, 9-diazadodecane," J. MED. CHEM., (1996) 39:339-41.	
CP**	Lloyd-Williams, P., "Convergent Solid-Phase Peptide Synthesis," TETRAHEDRON, (1993) 49(48): 11065-133.	
CQ**	Marton, L.J., et al., "Polyamines as Targets for Therapeutic Intervention," ANNU. REV. PHARMACOL. TOXICOL., (1995) 35:55-91.	
CR**	Muramoto, K., "Preparation and Characterization of Photoactivable Heterobifunctional Fluorescent Reagents," AGRIC. BIOL. CHEM., (1984) 48 (11), 2695-9.	
CS**	Nakaoka, T., et al., "Inhibition of Rat Vascular Smooth Muscle Proliferation In Vitro and In Vivo by Bone Morphogenetic Protein-2," J. CLIN. INVEST., (1997) 100 (11): 2824-32.	
CT**	Pfitzner, K.E., et al., "Sulfoxide-Carbodiimide Reactions. I.A Facile Oxidation of Alcohols," J. AM. CHEM. SOC., (1965) 87(24): 5661-9.	
CU**	Quemener, V., et al., "Polyamine Deprivation: A New Tool in Cancer Treatment," ANTICANCER RES., (1994) 14:443-8.	
CV**	Raines, D.E., et al., "Potential-Dependent Phase Partitioning of Fluorescent Hydrophobic Ions in Phospholipid Vesicles," J.MEMBRANE BIOL., (1984) 82:241-7.	
CW**	Rajeev, K.G., et al., "Conformationally Restrained Chiral Analogues of Spermine: Chemical Synthesis and Improvements in DNA Triplex Stability," J.ORG CHEM., (1997) 62:5169-73.	
CX**	Ranganathan, R.S., et al., "Novel Analogs of Nucleoside 3',5'-Cyclic Phosphates. I. 5'-Mono- and Dimethyl Analogs of Adenosine 3', 5'-Cyclic Phosphate," J. ORG. CHEM., (1974) 39(3):290-8.	
CY**	Rink, H., "Solid-phase synthesis of Protected Peptide Fragments Using A Trialkoxy-Diphenyl-Methylester Resin," TETRAHED. LETT., (1987) 28(33): 3787-90.	
CZ**	Salemme, F.R., et al., "Serendipity Meets Precision: The Integration of Structure-Based Drug Design and Combinatorial Chemistry for Efficient Drug Discovery," STRUCTURE, (1997) 5(3):319-24.	
CA1**	Sasaki, Y. et al., "Solid-Phase Synthesis and Biological Properties of Ψ[CH ₂ NH]	
	Pseudopeptide Analogues of a Highly Potent Somatostatin Octapeptide," J. MED. CHEM., (1987 30(7):1162-6.	
CB1**	Schallenberg, E.E., et al., "Ethyl Thioltriifluoroacetate As An Acetylating agent with Particular Reference to Peptide Synthesis," J.AM.CHEM.SOC., (1955) 77:2779-83.	
CC1**	CELL BIOL., (1996) 2898): 843-61.	
CD1**	22(3):211-8.	
CE1**	Shyng, SL., et al., "Depletion of Interacellular Polyamines Relieves Inward Rectification of Potassium Channels," PROC. NATL. ACAD. SCI. USA, (1996) 93:12014-9.	
CF1**	Siegel, M.G. et al., "Rapid Purification of Small Molecule Libraries b y Ion Exchange Chromatography," TETRAHEDRON LETT., (1997) 389(19): 3357-60.	
CG1**	Singh, S. et al., "Characterization of Simian Malarial Parasite (Plasmodium Knowlesi) -induced Putrescine Transport in Rhesus Monkey Erythrocytes," J. BIOL. CHEM., (1997) 272(21): 13506-11.	
CH1**	Thompson, L.A. et al., "Straightforward and General Method for Coupling Alcohols to Solid Supports," TETRAHED. LETT., (1994) 35:9333-6.	

Examiner	Date
Signature	Considered

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required t

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	3	of	3

o respond to a collection of information unless it contains a valid ONIB control number.				
Complete if Known				
09/396,523 Conf.# 7553				
September 15, 1999				
Christine L. O'Day				
1621				
P. G. O'Sullivan				
22116-00005-US3				

	CI1**	Ventura, C. et al., "Polyamine Effects on [Ca2+] 1 Homeostasis and Contractility in Isolated	
		Rat Ventricular Cardiomyocytes," AM. J. PHYSIOL., (1994) 267:H587-H592.	
C		Wang, SS., "p-Alkoxybenzyl Alcohol Resin and p-Alkoxybenzyloxycarbonylhydrazide Resin for Solid Phase Synthesis of Protected Peptide Fragments," J. AM. CHEM. SOC., (1973) 95(4): 1128-1333.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner	Date
Signature	Considered